Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.

Purpose: To evaluate the PK and safety of siponimod, a substrate of CYP2C9/3A4, in the presence or absence of a CYP3A4 inhibitor, itraconazole. Methods: This was an open-label study in healthy subjects (aged 18–50 years; genotype: CYP2C9 *1*2 [cohort 1; n = 17] or *1*3 [cohort 2; n = 13]). Subjects...

Full description

Bibliographic Details

Published in:	European Journal of Clinical Pharmacology Vol. 75; no. 11; pp. 1565 - 1575
Main Authors:	Gardin, Anne, Shakeri-Nejad, Kasra, Feller, Andrea, Huth, Felix, Neelakantham, Srikanth, Dumitras, Swati
Format:	clinical trial research tables/charts Journal Article
Published:	Springer Nature Nov2019
Online Access:	View this record in EBSCOhost